Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Community GuideSubcutaneous in guideDaily
Third-party educational schedule for a 10 mg research vial
2.5 mg once daily on days 1-2, then 5 mg once daily; the guide also discusses twice-daily use at the same per-administration quantities
This is a community-derived schedule, not a human clinical regimen. No controlled human administration study validates the route, escalation or duration.
View sourceEvidence summary
A small-molecule NNMT inhibitor with cell and animal metabolic research. It is not a peptide and no validated human protocol has been established.
Protocol basis
The page is based on preclinical NNMT-inhibition studies and therefore reports no human administration protocol.
What remains uncertain
Human safety, pharmacokinetics, target engagement and clinical outcomes are unknown.
Warnings and contraindications
No controlled human administration evidence was identified.
Rodent metabolic study quantities cannot be converted into a human schedule.
Identity, oral bioavailability and long-term NNMT inhibition risks remain uncertain.